碩世生物(688399.SH)一度拉昇漲超8% 針對武漢肺炎疫情研發出新型冠狀病毒檢測試劑盒
格隆匯1月14日丨碩世生物(688399.SH)14點後出現一波直線拉昇走勢,一度漲超8%至上市以來新高價67元,之後有所回落,最終收報63.1元,漲3.48%,成交1.37億元,最新總市值36.99億元。

碩世生物針對武漢肺炎疫情研發出新型冠狀病毒檢測試劑盒。
據媒體稱,武漢近期報告的肺炎疫情引發各界關注,為應對本次疫情新型冠狀病毒的檢測,碩世生物在拿到病毒序列後,第一時間就進行了新型冠狀病毒核酸檢測試劑盒(雙重熒光PCR法)的開發。同時,碩世生物還新開發出冠狀病毒通用型核酸檢測試劑盒,實現對OC43、NL63、HKU1、229E、SARS、MERS、新型冠狀病毒(2019)多種冠狀病毒的同時檢測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.